AIM Vaccine (HKG:6660) submitted the application for clinical trial of the iterative-process of its human diploid serum-containing rabies vaccine to the Center for Drug Evaluation of the National Medical Products Administration of China, a Thursday Hong Kong bourse filing said.
The company has already developed an iterative-process high-efficiency human diploid rabies vaccine workshop, up to the international standards, which is capable of large-scale production of the drug. The company has also produced commercial-scale phase 3 clinical trial samples of the drug.
Compared to other rabies vaccines in the market, the company's vaccine has overcome the blockages of low virus titer and low yield in the traditional process.
The vaccine has been optimized and innovated along with optimizing its safety and quality and its vaccination process is more flexible than the traditional drugs in the market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.